Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881896 | 0.92 | PTGER4 (0.57) | PTGER4HPGDTSHRKMT2AAAK1 | |
| SCHEMBL13876936 | 0.88 | PTGER4 (0.51) | PTGER4AAK1 | |
| SCHEMBL1609124 | 0.88 | PTGER4 (0.48) | PTGER4HDAC3HDAC1HDAC2CREBBP | |
| SCHEMBL3926362 | 0.87 | PTGER4 (0.49) | PTGER4HDAC3HDAC1HDAC2GRM4 | |
| SCHEMBL13885821 | 0.84 | MAPT (0.40) | PTGER4HPGDTSHRKMT2ACREBBP | |
| SCHEMBL10048485 | 0.84 | PTGER4 (0.47) | PTGER4HDAC1HDAC2HPGDTSHR | |
| SCHEMBL10048260 | 0.83 | MAPT (0.50) | HPGDKMT2A | |
| SCHEMBL3996157 | 0.81 | PTGER4 (0.67) | PTGER4HPGDCREBBP | |
| SCHEMBL14523936 | 0.81 | KMT2A (0.43) | PTGER4HPGDTSHRKMT2AGRM4 | |
| SCHEMBL5881733 | 0.79 | PTGER4 (0.56) | PTGER4HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| EP-1670769-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1670770-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1670790-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | F12, H1-3, H1-4 | PTGER4 32/4885HDAC3 165/4885HDAC1 171/4885 |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | PTGER4 46/4885HDAC3 36/4885HDAC1 108/4885 |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | PTGER4 102/4885HDAC3 604/4885HDAC1 985/4885 |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | CYP3A4, CYP2C19, H1-3 | PTGER4 54/4885HDAC3 27/4885HDAC1 74/4885 |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | TBXA2R, CYP2C19, CYP3A43 | PTGER4 37/4885HDAC3 20/4885HDAC1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.